[Clinical Study of Ibrutinib in the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma].

Q4 Medicine

中国实验血液学杂志 Pub Date : 2025-06-01 DOI:10.19746/j.cnki.issn.1009-2137.2025.03.023

Yu-Ning Yao, Hao Jiang, Lu-Min Tang, Ye Lou

{"title":"[Clinical Study of Ibrutinib in the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma].","authors":"Yu-Ning Yao, Hao Jiang, Lu-Min Tang, Ye Lou","doi":"10.19746/j.cnki.issn.1009-2137.2025.03.023","DOIUrl":null,"url":null,"abstract":"Objective: To study the clinical effects of ibrutinib in the treatment of relapsed/refractory diffuse large B-cell lymphoma (RRDLBCL).Methods: A total of 101 patients with RRDLBCL in Daqing People's Hospital from September 2019 to September 2022 were selected. 45 patients were received ibrutinib monotherapy, 36 patients were received a combination therapy of ibrutinib, rituximab, and lenalidomide, and 20 patients were received a combination therapy of ibrutinib and lenalidomide. The clinical effects were observed.Results: The median duration of treatment for all patients was 4 (2-9) months. The disease control rates(DCR) and objective response rates(ORR) in the ibrutinib monotherapy group were 46.67% and 26.67%, respectively. In the combination therapy group of ibrutinib, rituximab, and lenalidomide, the DCR and ORR were 69.44% and 44.44%, respectively. In the combination therapy group of ibrutinib and lenalidomide, the DCR and ORR were 60.00% and 35.00%, respectively. The DCR and ORR in the combination therapy group of ibrutinib, rituximab, and lenalidomide were significantly higher than those in the ibrutinib monotherapy group (P < 0.05). There were no significant differences in DCR and ORR between the combination therapy group of ibrutinib and lenalidomide and the ibrutinib monotherapy group (P >0.05). The median follow-up time of all patients was 15 (5-35) months, with a median overall survival(OS) of 21.0 (15.8-26.2) months and a median progression-free survival(PFS) of 14.0 (12.1-15.9) months. In the ibrutinib monotherapy group, the median OS and PFS were 15.0 (12.1-17.9) months and 12.0 (11.0-13.0) months, respectively. In the combination therapy group of ibrutinib and lenalidomide, the median OS and PFS were 22.0 (13.3-30.7) months and 16.0 (14.1-19.7) months, respectively. In the combination therapy group of ibrutinib, rituximab, and lenalidomide, the median OS and PFS were 23.0 (19.7-26.3) months and 17.0 (14.8-19.1) months, respectively. The median OS and PFS in the combination therapy group of ibrutinib, rituximab, and lenalidomide were significantly higher than those in the ibrutinib monotherapy group (P < 0.05). There were no significant differences in median OS and PFS between the combination therapy group of ibrutinib and lenalidomide and the combination therapy group of ibrutinib, rituximab, and lenalidomide (P >0.05). Hematological adverse reactions included neutropenia in 14 cases (13.86%), thrombocytopenia in 16 cases (15.84%), and leukopenia in 13 cases (12.87%). Non-hematological adverse reactions mainly included nausea and vomiting in 33 cases (32.67%) and fatigue in 44 cases (43.56%).Conclusion: Ibrutinib has certain clinical effects and good safety in the treatment of RRDLBCL.","PeriodicalId":35777,"journal":{"name":"中国实验血液学杂志","volume":"33 3","pages":"784-788"},"PeriodicalIF":0.0000,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"中国实验血液学杂志","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.19746/j.cnki.issn.1009-2137.2025.03.023","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

Abstract

Objective: To study the clinical effects of ibrutinib in the treatment of relapsed/refractory diffuse large B-cell lymphoma (RRDLBCL).

Methods: A total of 101 patients with RRDLBCL in Daqing People's Hospital from September 2019 to September 2022 were selected. 45 patients were received ibrutinib monotherapy, 36 patients were received a combination therapy of ibrutinib, rituximab, and lenalidomide, and 20 patients were received a combination therapy of ibrutinib and lenalidomide. The clinical effects were observed.

Results: The median duration of treatment for all patients was 4 (2-9) months. The disease control rates(DCR) and objective response rates(ORR) in the ibrutinib monotherapy group were 46.67% and 26.67%, respectively. In the combination therapy group of ibrutinib, rituximab, and lenalidomide, the DCR and ORR were 69.44% and 44.44%, respectively. In the combination therapy group of ibrutinib and lenalidomide, the DCR and ORR were 60.00% and 35.00%, respectively. The DCR and ORR in the combination therapy group of ibrutinib, rituximab, and lenalidomide were significantly higher than those in the ibrutinib monotherapy group (P < 0.05). There were no significant differences in DCR and ORR between the combination therapy group of ibrutinib and lenalidomide and the ibrutinib monotherapy group (P >0.05). The median follow-up time of all patients was 15 (5-35) months, with a median overall survival(OS) of 21.0 (15.8-26.2) months and a median progression-free survival(PFS) of 14.0 (12.1-15.9) months. In the ibrutinib monotherapy group, the median OS and PFS were 15.0 (12.1-17.9) months and 12.0 (11.0-13.0) months, respectively. In the combination therapy group of ibrutinib and lenalidomide, the median OS and PFS were 22.0 (13.3-30.7) months and 16.0 (14.1-19.7) months, respectively. In the combination therapy group of ibrutinib, rituximab, and lenalidomide, the median OS and PFS were 23.0 (19.7-26.3) months and 17.0 (14.8-19.1) months, respectively. The median OS and PFS in the combination therapy group of ibrutinib, rituximab, and lenalidomide were significantly higher than those in the ibrutinib monotherapy group (P < 0.05). There were no significant differences in median OS and PFS between the combination therapy group of ibrutinib and lenalidomide and the combination therapy group of ibrutinib, rituximab, and lenalidomide (P >0.05). Hematological adverse reactions included neutropenia in 14 cases (13.86%), thrombocytopenia in 16 cases (15.84%), and leukopenia in 13 cases (12.87%). Non-hematological adverse reactions mainly included nausea and vomiting in 33 cases (32.67%) and fatigue in 44 cases (43.56%).

Conclusion: Ibrutinib has certain clinical effects and good safety in the treatment of RRDLBCL.

查看原文本刊更多论文

伊鲁替尼治疗复发/难治性弥漫性大b细胞淋巴瘤的临床研究

目的：探讨依鲁替尼治疗复发/难治性弥漫性大b细胞淋巴瘤（RRDLBCL）的临床疗效。方法：选取2019年9月至2022年9月大庆市人民医院收治的101例RRDLBCL患者。45例患者接受依鲁替尼单药治疗，36例患者接受依鲁替尼、利妥昔单抗和来那度胺联合治疗，20例患者接受依鲁替尼和来那度胺联合治疗。观察临床疗效。结果：所有患者的中位治疗时间为4（2-9）个月。伊鲁替尼单药组疾病控制率（DCR）和客观缓解率（ORR）分别为46.67%和26.67%。依鲁替尼、利妥昔单抗和来那度胺联合治疗组，DCR和ORR分别为69.44%和44.44%。依鲁替尼与来那度胺联合治疗组DCR和ORR分别为60.00%和35.00%。依鲁替尼、利妥昔单抗、来那度胺联合治疗组的DCR、ORR均显著高于依鲁替尼单药治疗组（P < 0.05）。依鲁替尼联合来那度胺组与依鲁替尼单药组DCR、ORR比较，差异均无统计学意义（P < 0.05）。所有患者的中位随访时间为15（5-35）个月，中位总生存期（OS）为21.0（15.8-26.2）个月，中位无进展生存期（PFS）为14.0（12.1-15.9）个月。伊鲁替尼单药治疗组中位OS和PFS分别为15.0（12.1-17.9）个月和12.0（11.0-13.0）个月。依鲁替尼和来那度胺联合治疗组，中位OS和PFS分别为22.0（13.3-30.7）个月和16.0（14.1-19.7）个月。依鲁替尼、利妥昔单抗和来那度胺联合治疗组，中位OS和PFS分别为23.0（19.7-26.3）个月和17.0（14.8-19.1）个月。依鲁替尼、利妥昔单抗、来那度胺联合治疗组的中位OS和PFS均显著高于依鲁替尼单药治疗组（P < 0.05）。依鲁替尼与来那度胺联合治疗组与依鲁替尼与利妥昔单抗与来那度胺联合治疗组的中位OS和PFS比较，差异均无统计学意义（P < 0.05）。血液学不良反应包括中性粒细胞减少14例（13.86%），血小板减少16例（15.84%），白细胞减少13例（12.87%）。非血液学不良反应主要为恶心、呕吐33例（32.67%），疲劳44例（43.56%）。结论：依鲁替尼治疗RRDLBCL具有一定的临床疗效和良好的安全性。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊